Skip to main content

Types of COVID-19 vaccines in development

 


Known safety profile: inactivated vaccines better known than protein subunit and nucleic acid and these two are better than viral vector

Whole virus vaccines use a weakened (attenuated) or deactivated form of the pathogen that causes a disease to trigger protective immunity to it.  There are two types of whole virus vaccines. 

1. Live attenuated vaccines use a weakened form of the virus, which can still grow and replicate, but does not cause illness.

2. Inactivated vaccines contain viruses whose genetic material has been destroyed by heat, chemicals or radiation so they cannot infect cells and replicate, but can still trigger an immune response.

Both are known, tried and tested vaccination strategies, which form the basis of many existing vaccines – including those for yellow fever and measles, shingles (live attenuated vaccines), or seasonal influenza and hepatitis A (inactivated vaccines). 


ADVANTAGES AND DISADVANTAGES OF LIVE ATTENUATED VACCINES

Well-established technology

Strong immune response

Immune response involves B cells and T cells

Relatively simple to manufacture

Unsuitable for people with compromised immune systems

May trigger disease in very rare cases

Relatively temperature sensitive, so careful storage necessary


ADVANTAGES AND DISADVANTAGES OF INACTIVATED VIRUS VACCINES

Well-established technology

Suitable for people with compromised immune systems

No live components, so no risk of the vaccine triggering disease

Relatively simple to manufacture

Relatively stable

Booster shots may be required


Inactivated vaccines:

Three from China (Sinovac, China, Brazil, UAE, few other countries)

One from India (Covaxin, INDIA)

One from Khazakhstan










https://www.gavi.org/vaccineswork/what-are-whole-virus-vaccines-and-how-could-they-be-used-against-covid-19

Comments

Post a Comment

Popular posts from this blog

Mounjaro, Is it a game changer for weight loss and diabetes?

  MOUNJARO™ ( Tirzepatide) was approved for medical use in the United States in May 2022 WEIGHT LOSS: (Not approved by FDA for weight loss) Eli Lilly and Company is  finalizing an application to the U.S. Food and Drug Administration for fast-track approval to sell tirzepatide for chronic weight management. MOUNJARO™ is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated in adults for type 2 diabetes mellitus management. CONTRAINDICATIONS Personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2  Known serious all to tirzepatide or any of the excipients in MOUNJARO                                                                    ...
Post a Comment
Read more

Thyroid health- Quality of Life

  Let's get a TSH blood test for our family and friends Normal serum TSH ranges are higher in the  people age 70 to 80 years ; based on this, higher serum TSH goals may be needed as a patient ages.  The American Thyroid Association (ATA) suggests raising the target serum TSH to 4-6 m IU/L for 70 years-old and up The thyroid is a small, butterfly-shaped hormone-producing gland located at the front of the neck. The thyroid gland secretes two main hormones:  thyroxine (T-4) and triiodothyronine (T-3).   These hormones regulate energy levels, metabolism of fats, proteins and carbohydrates, body temperature, heart rate.  Hypothyroidism happens when the underactive thyroid gland doesn't make enough hormones. Hypothyroidism affects up to 10% of the general population (5% undiagnosed) . A n autoimmune disease called Hashimoto's diseas e where our body  makes antibodies that attack healthy thyroid tissues  is the most common cause of hypothyroidism in soc...
Post a Comment
Read more

Heart healthy

*Clinical atherosclerotic cardiovascular disease (ASCVD) includes acute coronary syndrome (ACS), those with history of myocardial infarction (MI), stable or unstable angina or coronary or other arterial revascularization, stroke, transient ischemic attack (TIA), or peripheral artery disease (PAD) including aortic aneurysm, all of atherosclerotic origin. Should I initiate statins or not? The 2014 National Lipid Association (NLA) recommendations provides a more comprehensive, patient-centered approach to identifying ASCVD risk.   In 2013, the American College of Cardiology and the American Heart Association (ACC/AHA) issued guidelines to use the intensity of statin therapy as the treatment goal instead of LDL-C or non–HDL-C targets, as in previous guidelines, to reduce atherosclerotic cardiovascular disease (ASCVD) risk (  Andrus & Lacaille, 2014  )  The guideline classifies statin therapy as  high-intensity (lowers LD...
7 comments
Read more